Infection and treatment immunizations for successful parasite vaccines

Trends in Parasitology

Volumn 29, Issue 3, 2013, Pages 135-141

  Mutapi, Francisca ^a   Billingsley, Peter F ^b   Secor, W Evan ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b SANARIA INC   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Immunization; Malaria; Parasite; Schistosomiasis; Treatment; Vaccine

Indexed keywords

ANTHRAX VACCINE; BCG VACCINE; CHICKENPOX VACCINE; CHLOROQUINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; PLASMODIUM FALCIPARUM ATTENUATED SPOROZOITE VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PRAZIQUANTEL; RABIES VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; SPOROZOITE VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; CONCEPTUAL FRAMEWORK; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALARIA; MEMORY T LYMPHOCYTE; NONHUMAN; REVIEW; SCHISTOSOMIASIS; VACCINATION;

ANIMALS; HUMANS; IMMUNIZATION; MALARIA VACCINES; PARASITES; PARASITIC DISEASES; PROTOZOAN VACCINES; SCHISTOSOMIASIS; VACCINES, SYNTHETIC;

EID: 84874252669     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2013.01.003     Document Type: Review

References (90)

1. Pichichero M.E. Booster vaccinations: can immunologic memory outpace disease pathogenesis?. Pediatrics 2009, 124:1633-1641.
2. Meeusen E.N., Piedrafita D. Exploiting natural immunity to helminth parasites for the development of veterinary vaccines. Int. J. Parasitol. 2003, 33:1285-1290.
3. Meeusen E.N., et al. Current status of veterinary vaccines. Clin. Microbiol. Rev. 2007, 20:489-510.
4. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47:401-409.
5. Nadim A., et al. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. Filiales 1983, 76:377-383.
6. Hoffman S.L., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 2010, 6:97-106.
7. Roestenberg M., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 2013, 88:5-13.
8. Roestenberg M., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377:1770-1776.
9. Bethony J.M., et al. Vaccines to combat the neglected tropical diseases. Immunol. Rev. 2011, 239:237-270.
10. Woolhouse M.E.J., Hagan P. Seeking the ghost of worms past. Nat. Med. 1999, 5:1225-1227.
11. Gupta S., et al. Acquired immunity and postnatal clinical protection in childhood cerebral malaria. Proc. Biol. Sci. 1999, 266:33-38.
12. Good M.F. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. 2005, 21:29-34.
13. Yazdanbakhsh M., Sacks D.L. Why does immunity to parasites take so long to develop?. Nat. Rev. Immunol. 2010, 10:80-81.
14. Mutapi F., et al. Age-related and infection intensity-related shifts in antibody recognition of defined protein antigens in a schistosome-exposed population. J. Infect. Dis. 2008, 198:167-175.
15. Hashemitabar G.R., et al. Trials to induce protective immunity in mice and sheep by application of protoscolex and hydatid fluid antigen or whole body antigen of Echinococcus granulosus. J. Vet. Med. B: Infect. Dis. Vet. Public Health 2005, 52:243-245.
16. Lightowlers M.W. Vaccination against hydatid disease. Dev. Biol. (Basel) 2002, 110:81-87.
17. Wilson R.A., Coulson S.R. Strategies for a schistosome vaccine: can we manipulate the immune response effectively?. Microbes Infect. 1999, 1:535-543.
18. Wilson R.A. Virulence factors of schistosomes. Microbes Infect. 2012, 14:1442-1450.
19. Roestenberg M., et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 2009, 361:468-477.
20. Mota M.M., et al. Migration of Plasmodium sporozoites through cells before infection. Science 2001, 291:141-144.
21. Craig A. Antigenic Variation 2003, Elsevier.
22. Kusi K.A., et al. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS ONE 2009, 4:e8110.
23. Cowan G.J., et al. A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. PLoS ONE 2011, 6:e26616.
24. DeMarco R., et al. Protein variation in blood-dwelling schistosome worms generated by differential splicing of micro-exon gene transcripts. Genome Res. 2010, 20:1112-1121.
25. Nausch N., et al. Regulatory and activated T cells in human Schistosoma haematobium infections. PLoS ONE 2011, 6:e16860.
26. Plebanski M., et al. Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology 1997, 115(Suppl.):S55-S66.
27. Butterworth A.E., et al. Immunity in human Schistosomiasis mansoni: cross reactive IgM and IgG2 anti-carbohydrate antibodies block the expression if immunity. Biochimie 1988, 70:1053-1063.
28. Capron A., et al. Development of a vaccine strategy against human and bovine schistosomiasis. Background and update. Trop. Geogr. Med. 1994, 46:242-246.
29. Everts B., et al. Schistosome-derived omega-1 drives Th2 polarization by suppressing protein synthesis following internalization by the mannose receptor. J. Exp. Med. 2012, 209:1753-1767.
30. Raberg L., et al. On the adaptive significance of stress-induced immunosuppression. Proc. Biol. Sci. 1998, 265:1637-1641.
31. Zhang W., et al. Mechanisms of immunity in hydatid disease: implications for vaccine development. J. Immunol. 2008, 181:6679-6685.
32. Ho M., et al. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J. Infect. Dis. 1986, 153:763-771.
33. Casares S., Richie T.L. Immune evasion by malaria parasites: a challenge for vaccine development. Curr. Opin. Immunol. 2009, 21:321-330.
34. Orengo J.M., et al. A Plasmodium yoelii soluble factor inhibits the phenotypic maturation of dendritic cells. Malar. J. 2008, 7:254.
35. Jangpatarapongsa K., et al. Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Eur. J. Immunol. 2008, 38:2697-2705.
36. Mellouk S., et al. Protection against malaria induced by irradiated sporozoites. Lancet 1990, 335:721.
37. Yayon A., et al. Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro. J. Protozool. 1983, 30:642-647.
38. Bejon P., et al. The induction and persistence of T cell IFN-γ responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J. Immunol. 2007, 179:4193-4201.
39. Belnoue E., et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 2004, 172:2487-2495.
40. Sutherland C.J., et al. How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions?. Malar. J. 2007, 6:161.
41. Gopinath R., et al. Long-term persistence of cellular hyporesponsiveness to filarial antigens after clearance of microfilaremia. Am. J. Trop. Med. Hyg. 1999, 60:848-853.
42. Maizels R.M., et al. Helminth parasites - masters of regulation. Immunol. Rev. 2004, 201:89-116.
43. Siracusano A., et al. Immunomodulatory mechanisms during Echinococcus granulosus infection. Exp. Parasitol. 2008, 119:483-489.
44. Taylor M.D., et al. Removal of regulatory T cell activity reverses hyporesponsiveness and leads to filarial parasite clearance in vivo. J. Immunol. 2005, 174:4924-4933.
45. Wilson M.S., et al. Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J. Exp. Med. 2005, 202:1199-1212.
46. Wilson M.S., et al. IL-10 blocks the development of resistance to re-infection with Schistosoma mansoni. PLoS Pathog. 2011, 7:e1002171.
47. Diaz A., Allen J.E. Mapping immune response profiles: the emerging scenario from helminth immunology. Eur. J. Immunol. 2007, 37:3319-3326.
48. - Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 2007, 204:273-283.
49. Loke P., et al. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol. 2002, 3:7.
50. Jenkins S.J., Allen J.E. Similarity and diversity in macrophage activation by nematodes, trematodes, and cestodes. J. Biomed. Biotechnol. 2010, 2010:262609.
51. Wilson M.S., et al. Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J. Immunol. 2008, 181:6942-6954.
52. Babu S., et al. Alternatively activated and immunoregulatory monocytes in human filarial infections. J. Infect. Dis. 2009, 199:1827-1837.
53. Lyke K.E., et al. HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. Infect. Immun. 2005, 73:5799-5808.
54. Allen J.E., Maizels R.M. Diversity and dialogue in immunity to helminths. Nat. Rev. Immunol. 2011, 11:375-388.
55. + cells after chemotherapy in human Schistosoma haematobium infection. Eur. J. Immunol. 1996, 26:1365-1370.
56. Watanabe K., et al. T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment. Am. J. Trop. Med. Hyg. 2007, 77:676-682.
57. Mitchell K.M., et al. The predicted impact of immunosuppression upon population age-intensity profiles for schistosomiasis. Parasite Immunol. 2008, 30:462-470.
58. Mitchell K.M., et al. Protective immunity to Schistosoma haematobium infection is primarily an anti-fecundity response stimulated by the death of adult worms. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:13347-13352.
59. Fulford A.C.J., et al. A statistical approach to schistosome population dynamics and estimation of the life-span of Schistosoma mansoni in man. Parasitology 1995, 110:307-316.
60. Bull P.C., Marsh K. The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol. 2002, 10:55-58.
61. Boyd M.F. Malariology 1949, Saunder.
62. Woolhouse M.E. Immunoepidemiology of human schistosomes: taking the theory into the field. Parasitol. Today 1994, 10:196-202.
63. Mutapi F., et al. Comparison of humoral responses to Schistosoma haematobium in areas with high and low levels of infection. Parasite Immunol. 1997, 19:255-263.
64. Mutapi F., et al. Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J. Infect. Dis. 2005, 192:1108-1118.
65. Hsu S.Y., et al. Schistosoma mansoni: vaccination of mice with highly x-irradiated cercariae. Exp. Parasitol. 1981, 52:91-104.
66. + T cells. J. Immunol. 2011, 187:3511-3520.
67. Borkow G., et al. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J. Clin. Invest. 2000, 106:1053-1060.
68. Griffith Q.K., et al. CD23-bound IgE augments and dominates recall responses through human naive B cells. J. Immunol. 2011, 186:1060-1067.
69. Struik S.S., Riley E.M. Does malaria suffer from lack of memory?. Immunol. Rev. 2004, 201:268-290.
70. Langhorne J., et al. Immunity to malaria: more questions than answers. Nat. Immunol. 2008, 9:725-732.
71. Cavanagh D.R., et al. A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J. Immunol. 1998, 161:347-359.
72. Dorfman J.R., et al. B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area. J. Infect. Dis. 2005, 191:1623-1630.
73. Akpogheneta O.J., et al. Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect. Immun. 2008, 76:1748-1755.
74. Polley S.D., et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006, 24:4233-4246.
75. Osier F.H., et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 2008, 76:2240-2248.
76. Wipasa J., et al. Short-lived IFN-γ effector responses, but long-lived IL-10 memory responses, to malaria in an area of low malaria endemicity. PLoS Pathog. 2011, 7:e1001281.
77. Wipasa J., et al. Long-lived antibody and B cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. 2010, 6:e1000770.
78. Agnandji S.T., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365:1863-1875.
79. Whitty C.J., et al. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans. R. Soc. Trop. Med. Hyg. 2000, 94:531-534.
80. Tchuente L.A., et al. Efficacy of praziquantel against Schistosoma haematobium infection in children. Am. J. Trop. Med. Hyg. 2004, 71:778-782.
81. Soonawala D., et al. The immune response to schistosome antigens in formerly infected travelers. Am. J. Trop. Med. Hyg. 2011, 84:43-47.
82. Van der Kleij D., et al. Triggering of innate immune responses by schistosome egg glycolipids and their carbohydrate epitope GalNAcβ1-4(Fucα1-2Fucα1-3)GlcNAc. J. Infect. Dis. 2002, 185:531-539.
83. Swain S. Grand challenges in immunological memory. Front. Immunol. 2010, 1:103.
84. + T cell recall responses is controlled by the duration of the secondary stimulus. J. Immunol. 2009, 183:2382-2389.
85. Pichichero M.E. Bacterial conjunctivitis in children: antibacterial treatment options in an era of increasing drug resistance. Clin. Pediatr. (Phila) 2011, 50:7-13.
86. Brake D.A. Parasites and immune responses: memory illusion?. DNA Cell Biol. 2003, 22:405-419.
87. + memory T cells are altered in individuals chronically infected with Schistosoma haematobium. Sci. Rep. 2012, 2:472.
88. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25:585-621.
89. Pilyugin S., et al. Modeling T-cell proliferation: an investigation of the consequences of the Hayflick limit. J. Theor. Biol. 1997, 186:117-129.
90. Ballou W.R. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 2009, 31:492-500.